Evidence map›Paper›PMID 35018375›Full record

ArticlebioRxiv : the preprint server for biology2022

Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2.

Xuan Yang, Rebekah J Dickmander, Armin Bayati, Sharon A Taft-Benz, Jeffery L Smith, Carrow I Wells, Emily A Madden, Jason W Brown, Erik M Lenarcic, Boyd L Yount and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Xuan YangStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Rebekah J DickmanderRapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, United States.
Armin BayatiStructural Genomics Consortium, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.
Sharon A Taft-BenzRapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, United States.
Jeffery L SmithStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Carrow I WellsStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Emily A MaddenDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jason W BrownTakeda San Diego, San Diego, CA 92121, United States.
Erik M LenarcicRapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, United States.
Boyd L YountDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Edcon ChangTakeda San Diego, San Diego, CA 92121, United States.
Alison D AxtmanStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Ralph S BaricRapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, United States.
Mark T HeiseRapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, United States.
Peter S McPhersonStructural Genomics Consortium, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.
Nathaniel J MoormanRapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, United States.
Timothy M WillsonStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
NIDDK NIH HHS U24 DK116204Wellcome Trust
6 · The paper itself

Abstract

Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein uptake was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for development of new broad spectrum anti-β-coronavirus drugs. GRAPHICAL ABSTRACT:

Identifiers

PMID35018375
PMCPMC8750650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.